Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that first- and second-line use of Boehringer Ingelheim/Pfizer's Spiriva in the treatment of chronic obstructive pulmonary disease (COPD) will grow as COPD prescribing patterns shift over the next two years. Although the long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) Advair (from GlaxoSmithKline) leads the long-acting muscarinic antagonist (LAMA) Spiriva in first- and second-line patient share in the treatment of COPD, our physician survey reveals that more physicians project an increase in their prescriptions for LAMAs than for LABA/ICS combinations in COPD. Fifty-five percent of pulmonologists and 41 percent of primary care physicians expect to increase their first-line use of LAMAs over the next two years. In addition, 23 percent of primary care physicians and 12 percent of pulmonologists indicate that they will increase their use of LAMAs as second- line therapies.

According to the new report entitled Treatment Algorithms in Chronic Obstructive Pulmonary Disease, more than 75 percent of patients newly diagnosed with the disease do not receive pharmacological treatment within 360 days of their diagnosis. Surveyed pulmonologists blame the low drug-treatment rate on mild disease, lack of physician awareness and cost of therapy.

"Surveyed pulmonologists and primary care physicians believe that improvements in screening and diagnosis will form a cornerstone of their COPD treatment going forward," said Madhuri Borde, Ph.D., analyst at Decision Resources. "Twenty-five percent of pulmonologists and 40 percent of primary care physicians plan to increase their use of spirometry in COPD diagnosis, which will allow for more optimal staging of disease severity. Physicians are also aware of the need to become more proactive about COPD diagnosis; 24 percent of pulmonologists and 43 percent of primary care physicians will perform lung-function tests more often in patients at risk for COPD."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

  -- Summary of U.S. medical practice based on interviews with leading      experts in the field.   -- Qualitative diagnosis/referral/treatment algorithm for the United      States.   -- Drug usage by lines of therapy (1st, 2nd, 3rd line).   -- Discussion of key freeform combinations by lines of therapy.   -- Product share (class and specific compound level) within each line of      therapy (1st, 2nd, 3rd line).   -- Progression of therapy from key 1st line products.   -- Pathway to key therapies from previous therapies.   -- Qualitative analysis of two-year forecast incorporating upcoming      launches, changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., (www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Most Hospital Pharmacy and Therapeutics Committee Members Anticipate that Drugs from Johnson & Johnson/Basilea and Theravance/Astellas will Achieve Formulary Inclusion Among Hospitals but with Restrictions

View Now